ZIVO Bioscience, Inc.
ZIVO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | 0.14 | -0.03 | 0.38 |
| FCF Yield | -0.44% | -0.84% | -2.23% | -1.24% |
| EV / EBITDA | -60.31 | -35.26 | -15.33 | -45.12 |
| Quality | ||||
| ROIC | 35.82% | 92.69% | 723.29% | 612.74% |
| Gross Margin | 32.44% | 33.56% | 0.00% | 30.00% |
| Cash Conversion Ratio | 0.26 | 0.29 | 0.34 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 136.26% | 250.84% | 495,189.09% | 539,620.93% |
| Free Cash Flow Growth | 44.05% | 66.69% | -57.91% | 16.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | -0.47 | -0.09 | 0.81 |
| Interest Coverage | 78.58 | -221.86 | -1,753.66 | -321.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,015.68 | -2,126.10 | 0.00 | -1,057.58 |